Hypha exemplify expertise in creation of non-CYP metabolites in Winter 2013 newsletter

Hypha’s microbial technology continues to develop as a solution to identify and produce challenging DMPK metabolites and has recently shown broader capabilities to mimic non-CYP metabolism, in addition to phase I human CYP metabolites and phase II glucuronides. Click here for the newsletter.